// App-Quantinova.ai

FRI0108 : RISK FOR HERPES ZOSTER AFTER TREATMENT WITH BIOLOGIC AND SYNTHETIC DISEASE MODIFYING AGENTS FOR RHEUMATOID ARTHRITIS

Researchers

Presenter

  • D.A. Pappas

Principal Investigators

  • M. Hooper

  • G. Reed

  • Y. Shan

  • D. Wenkert

  • J. Zhang

  • J. Greenberg

  • J. Curtis

Medical Centers

  • NYU Langone Medical School, New York, United States

Locations

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Rheumatoid arthritis

  • Diabetes

  • Shingles

  • Inflammatory Arthritis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Methotrexate

  • HWA-486

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved